ClinicalTrials.gg
CompletedNCT02651870Updated Aug 25, 2020

Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

A Phase 3 interventional study of Candesartan 16mg and Amlodipine 5mg in Hypertension, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2020-08-25.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Apr 2015, registered Jan 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
109th of 186
135 · median 180
Started
2015
with 8 others
Phase 3
69 of 187
2 open now
Registered
132nd of 187
by date

Among the 187 studies testing amlodipine in Hypertension, this one is the 109th largest by enrollment of the 186 interventional ones that give a count, is one of 9 that started in 2015, is one of 69 in phase 3, and was the 132nd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

A Phase 3 Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 19 or above
  • Inadequately controlled Essential hypertension at Screening

    1. Drug naive or didn't take antihypertensive drug within 2 weeks prior to Visit 1

      • Mean sitDBP ≥ 95mmHg on target arm
    2. Taking antihypertensive drug but not controlled

      • Mean sitDBP ≥ 90mmHg on target arm
  • Inadequately controlled after 4 weeks of Candesartan 16mg monotherapy

    • Mean sitDBP at Visit 2 ≥ 90mmHg on target arm
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • The change of mean sitDBP ≥ 10mmHg or mean sitSBP ≥ 20mmHg on target arm at Visit 1
  • Mean sitDBP ≥ 120mmHg or mean sitSBP ≥ 200mmHg on target arm at Visit 1 and Visit 2
  • Known to suspected Stage 2 Hypertension(aortic coarctation, Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma)
  • Patient with congestive heart failure( class III, IV)
  • Patient with unstable angina pectoris, myocardial infarction, Valvular heart disease, arrhythmia(treatment required) within 3 months
  • History of stroke, cerebral hemorrhage within 6 months
  • Type I Diabetes mellitus, Type II Diabetes mellitus with > 8.5%
  • History of severe or malignant retinopathy
  • /ALT > UNL*3, Serum creatinine > UNL*1.5, K > 5.5mEq/L
  • Patient with acute or chronic inflammatory(treatment required) status
  • Patient who need to take antihypertensive drug besides products
  • Patient must be treated with medications prohibited for concomitant use during the study period
  • History of angioedema related to ACE inhibitor or angiotensin II receptor blockers
  • Hypersensitive to Candesartan/Amlodipine
  • Patient who are dependent on drugs or alcohol within 6 months
  • History of disability to drug ADME, active inflammatory bowel syndrome within 12months, impaired pancreatic function, GI bleeding, obstructions of urinary tract
  • Patients treated with other investigational product within 30 days at first time taking the investigational product
  • Women with pregnant, breast-feeding
  • History of malignant tumor within 5 years
  • Not eligible to participate for the study at the discretion of investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Candesartan 16mg + Amlodipine 5mg

    Candesartan 16mg + Amlodipine 5mg, po, q.d.

    Drug: Candesartan 16mg · Drug: Amlodipine 5mg

  • Experimental
    Candesartan 16mg + Amlodipine 10mg

    Candesartan 16mg + Amlodipine 10mg, po, q.d.

    Drug: Candesartan 16mg · Drug: Amlodipine 10mg

  • Active comparator
    Candesartan 16mg

    Candesartan 16mg, po, q.d.

    Drug: Candesartan 16mg

06

What researchers measure

Primary outcomes

  1. The mean change of sitDBP(sitting diastolic blood pressure)

    Time frame: From baseline at week 8

Secondary outcomes

  1. The mean change of sitDBP

    Time frame: From baseline to week 4

  2. The mean change of sitSBP

    Time frame: From baseline to week 4 and 8

  3. Control rate: Patient achieving sitSBP < 140mmHg and sitDBP < 90mmHg

    Time frame: From baseline to week 8

  4. Response rate: sitSBP reduction ≥ 20mmHg and sitDBP reduction ≥ 10mmHg

    Time frame: From baseline to week 8

07

Study locations

1 site
  • Severance Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Feb 2016, 10 months.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 10 months is below that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2016
First posted
Jan 11, 2016
StartActual
Apr 22, 2015
Primary completionActual
Feb 25, 2016
CompletionActual
Feb 29, 2016
Last update
Aug 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02651870
Responsible party
Sponsor
First posted
Jan 11, 2016
Start date
Apr 22, 2015
Primary completion
Feb 25, 2016
Completion
Feb 29, 2016
Last update
Aug 25, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion